Paul Legendre
Overview
Explore the profile of Paul Legendre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baber A, Legendre P, Chauvet S, Karras A, Deshayes S, Huart A, et al.
Kidney Int Rep
. 2024 Mar;
9(3):712-716.
PMID: 38481513
No abstract available.
2.
Baber A, Legendre P, Palmic P, Lupo-Mansuet A, Burroni B, Azoulay C, et al.
Int J Surg Pathol
. 2023 May;
32(1):150-154.
PMID: 37157817
EBV-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm almost exclusively located in the spleen or liver. It is characterized by a proliferation of EBV-positive spindle-shaped...
3.
Sorin B, Iudici M, Guerry M, Samson M, Bielefeld P, Maillet T, et al.
Rheumatology (Oxford)
. 2023 Feb;
62(11):3662-3671.
PMID: 36847447
Objective: To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy. Methods: We conducted a nationwide retrospective case-control study of GPA with...
4.
Breillat P, Mariampillai K, Legendre P, Martins P, Dunogue B, Charuel J, et al.
Rheumatology (Oxford)
. 2022 Sep;
62(4):1467-1475.
PMID: 36063462
Objective: To help identify homogeneous subgroups among patients with anti-PM-scleroderma-antibodies (PM-Scl-Abs) positive auto-immune diseases regardless of diagnostic classifications. Material And Methods: This multicentric (four hospitals) retrospective study collected all consecutive...
5.
Tieu A, Chaigne B, Dunogue B, Dion J, Regent A, Casadevall M, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626223
Objective: to describe the prevalences, characteristics, and survivals of patients with anti-topoisomerase 1 antibodies (ATA) and limited cutaneous systemic sclerosis (lSSc) and anti-centromere antibodies (ACA) and diffuse cutaneous systemic sclerosis...
6.
Martellosio J, Gastli N, Farhat R, Tazi A, Duraffour P, Rossi B, et al.
Ocul Immunol Inflamm
. 2022 Apr;
31(5):905-913.
PMID: 35413213
Introduction: (KP) is the most common cause of endogenous endophthalmitis (EE) in Asia, but data in Europe are scarce. We describe eight cases of KP EE compared to a cohort...
7.
Furtado S, Dunogue B, Jourdi G, Chaigne B, Chibah A, Legendre P, et al.
J Scleroderma Relat Disord
. 2022 Apr;
6(2):178-186.
PMID: 35386738
Objective: To determine the frequency of elevated D-dimer plasma concentration (>500 ng/mL) in patients with systemic sclerosis and evaluate its association with systemic sclerosis-specific microvascular and macrovascular complications. Methods: Retrospective...
8.
Legendre P, Blanchet B, Porcher R, Berezne A, Allard M, London J, et al.
J Scleroderma Relat Disord
. 2022 Apr;
6(1):87-95.
PMID: 35382246
Objective: To explore pharmacokinetic/pharmacodynamic relationship between mycophenolic acid area under the curve and clinical response at 1 year on skin involvement or interstitial lung disease in patients with systemic sclerosis....
9.
Mettler C, Petit C, Ernest V, Asli B, Daniel M, Mathis S, et al.
Clin Immunol
. 2022 Feb;
236:108951.
PMID: 35134549
Erythroblastic synartesis is a rare cause of acquired dyserythropoiesis. Only 9 cases have been previously reported. We hereby report 3 cases of patients diagnosed with erythroblastic synartesis associated with monoclonal...
10.
Sorin B, Samson M, Durel C, Diot E, Guichard I, Grados A, et al.
Rheumatology (Oxford)
. 2021 Oct;
61(6):2619-2624.
PMID: 34698818
Objective: The aim of this study was to describe the efficacy and safety of rituximab and MTX (RTX/MTX) combination therapy in ANCA-associated vasculitides (AAV). Methods: A retrospective French nationwide study...